Managing iron deficiency anemia of CKD with IV iron

U.S. Pharmacist

Volumn 38, Issue 8, 2013, Pages 22-26

  Krikorian, Susan ^a   Shafai, Gigi ^b   Shamim, Kanza ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRITIN; FERUMOXYTOL; IRON DEXTRAN; IRON SACCHARATE; TRANSFERRIN;

ANTIGEN ANTIBODY REACTION; ARTICLE; BIOAVAILABILITY; CHRONIC KIDNEY DISEASE; DEGRADATION KINETICS; ERYTHROPOIESIS; HEART INFARCTION; HEMOCHROMATOSIS; HEMODIALYSIS PATIENT; HUMAN; INTESTINE ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; MEDICATION COMPLIANCE; MOLECULAR SIZE; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 84882805410     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (39)

1. World Health Organization. Nutritional anaemias. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1968;405:5-37.
2. Adamson JW, Longo DL. Anemia and polycythemia. In: Longo DL, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill; 2012.
3. Lerma EV. Anemia of chronic disease and renal failure. Medscape. http://emedicine.medscape.com/article/1389854. Accessed May 8, 2013.
4. Streja E, Miller JE, Nissenson AR. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia? ACKD. 2009;16:143-151.
5. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11-S145.
6. Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002;162:1401-1408.
7. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66:753-760.
8. Silverberg DS, Wexler D, Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol. 2004;17:749-761.
9. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501-1510.
10. Irwin C, Moriarity-Suggs C. Anemia management in chronic and end-stage kidney disease. US Pharm. 2010;35(3)(Oncology/Hematology suppl):8-13.
11. Pasricha SR. Is it time for hepcidin to join the diagnostic toolkit for iron deficiency? Expert Rev Hematol. 2012;5:153-155.
12. Singh AK, Szczech L, Tang KL, et al; CHOIR investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.
13. Drüeke TB, Locatelli F, Clyne N, et al; CREATE investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
14. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.
15. Coyne DW. It's time to compare anemia management strategies in hemodialysis. Clin J Am Soc Nephrol. 2010;5:740-742.
16. Coyne DW. A comprehensive vision for intravenous iron therapy. Am J Kidney Dis. 2008;52(6 suppl):S14-S20.
17. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol. 2007;18:382-393.
18. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010;6:699-710.
19. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.
20. Auerbach M, Coyne D, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol. 2008;83: 580-588.
21. Silverstein SB, Gilreath JA, Rodgers GM. Intravenous iron therapy: a summary of treatment options and review of guidelines. J Pharm Pract. 2008;21:431-443.
22. Yessayan L, Sandhu A, Besarab A, et al. Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy. Int J Nephrol. 2013;2013:703038. doi:10.1155/2013/703038.
23. DexFerrum (iron dextran injection) product information. Shirley, NY: American Regent, Inc; 2008.
24. INFeD (iron dextran injection) product information. Morristown, NJ: Watson Pharma, Inc; September 2009.
25. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-382.
26. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011;3:12-33.
27. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm. 2012;69:310-320.
28. Ferrlecit (sodium ferric gluconate complex in sucrose injection) product information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; August 2011.
29. Venofer (iron sucrose injection) product information. Shirley, NY: American Regent, Inc; September 2012.
30. Coppol E, Shelly J, Cheng S, et al. A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population. Ann Pharmacother. 2011;45:241-247.
31. Van Wyck DB, Bailie G, Aronoff G. Just the FAQs: frequently asked questions about iron and anemia in patients with chronic kidney disease. Am J Kidney Dis. 2002;39:426-432.
32. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology American Soc Hematol Educ Program. 2010;2010:338-347.
33. Feraheme (ferumoxytol) product information. Lexington, MA: AMAG Pharmaceuticals, Inc; November 2011.
34. Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012;59:444-451.
35. Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther. 2011;5:51-60.
36. SFP clinical development progress. www.rockwellmed.com/bio-pharma-soluble-ferric-pyrophosphate-clinical-development.htm. Accessed July 18, 2013.
37. Garneata L. Intravenous iron, inflammation, and oxidative stress: is iron a friend or an enemy of uremic patients? J Ren Nutr. 2008;18:40-45.
38. Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res. 2008;6:93-102.
39. Pai AB, Conner TA. Oxidative stress and inflammation in chronic kidney disease: role of intravenous iron and vitamin D. J Pharm Pract. 2008;21:214-224.